Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

125
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
125
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

79
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
79
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

98
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
98
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

934
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
934
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

46
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
46

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gelsolin-3: A Novel Myelin Autoantigen in Demyelinating Guillain-Barré Syndrome.

Annals of neurology·2026
Same author

Unveiling a Regional Variant of Demyelinating Guillain-Barré Syndrome: Nerve Conduction Study Evidence in Bifacial Weakness With Paresthesias.

Journal of the peripheral nervous system : JPNS·2026
Same author

Effectiveness of satralizumab in a real-world clinical setting in Japan: Interleukin-6 receptor inhibition in neuromyelitis optica spectrum disorder: A six-month interim analysis of a multicenter medical chart review.

Multiple sclerosis and related disorders·2025
Same author

Prevalence, clinical profiles, and prognosis of Isaacs syndrome: A nationwide survey study in Japan.

Journal of the neurological sciences·2025
Same author

IgG subclass shifts occurring at acute exacerbations in autoimmune nodopathies.

Journal of neurology·2024
Same author

Proteinuria is a key to suspect autoimmune nodopathies.

European journal of neurology·2024

Related Experiment Video

Updated: May 8, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.1K

[Treatment Strategies for Chronic Inflammatory Demyelinating Polyneuropathy].

Norito Kokubun1

  • 1Department of Neurology, Dokkyo Medical University.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|December 26, 2024
PubMed
Summary

Effective management of chronic inflammatory demyelinating polyneuropathy (CIDP) requires considering both induction and maintenance therapies. Treatment options include plasma exchange, immunoglobulin therapy, and corticosteroids, often used in combination.

More Related Videos

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

26.9K
In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells
08:57

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

Published on: February 10, 2023

1.9K

Related Experiment Videos

Last Updated: May 8, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.1K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

26.9K
In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells
08:57

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

Published on: February 10, 2023

1.9K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder affecting peripheral nerves.
  • Effective management strategies are crucial for improving patient outcomes and quality of life.
  • Current treatment paradigms necessitate a comprehensive approach addressing both acute and long-term disease phases.

Purpose of the Study:

  • To outline the primary treatment modalities for chronic inflammatory demyelinating polyneuropathy (CIDP).
  • To emphasize the importance of distinct induction and maintenance therapeutic strategies in CIDP management.
  • To review the efficacy of various treatment options, including immunomodulatory and immunosuppressive therapies.

Main Methods:

  • Review of established and emerging treatments for CIDP.
  • Analysis of therapeutic approaches for both disease induction and long-term maintenance.
  • Consideration of combination therapies for comprehensive patient management.

Main Results:

  • Plasma exchange and intravenous immunoglobulin (IVIg) are effective induction treatments for CIDP.
  • Corticosteroids demonstrate efficacy in both induction and maintenance phases of CIDP.
  • Repeat IVIg or subcutaneous immunoglobulin infusions represent a viable maintenance therapy option.

Conclusions:

  • A tailored approach integrating induction and maintenance therapies is essential for optimal CIDP management.
  • Combination strategies utilizing plasma exchange, immunoglobulin therapy, and corticosteroids offer flexible treatment options.
  • Ongoing research and clinical practice should focus on personalized treatment plans for CIDP patients.